Human papillomavirus (HPV) can successfully evade the host immune response to establish a persistent infection. We show here that expression of the E7 oncoprotein in primary human keratinocytes results in increased production of interleukin-18 (IL-18) binding protein (IL-18BP). This anti-inflammatory protein is a natural antagonist of IL-18 and is necessary for skin homeostasis. We map increased IL-18BP production to the CR3 region of E7 and demonstrate that this ability is shared among E7 proteins from different HPV types. Furthermore, mutagenesis shows that increased IL-18BP production is mediated by a gamma-activated sequence (GAS) in the IL-18BP promoter. Importantly, the increased IL-18BP levels seen in E7-expressing keratinocytes are capable of diminishing IL-18-mediated CD4 lymphocyte activation. This study provides the first evidence for a virus protein that targets IL-18BP and further validates E7 as a key component of the HPV immune evasion armor.
H
uman papillomaviruses (HPVs) are small double-stranded DNA (dsDNA) viruses that infect squamous epithelial cells and produce a range of clinical lesions ranging from common warts to cancers of the anogenital tract and oropharynx. More than 100 types have been identified (1) and are classified as either low-or high-risk types, depending on the associated risk of cancer development. High-risk HPVs are responsible for the majority of cervical cancers and a subset of head and neck squamous cell carcinomas (2) , and among these, HPV16 is detected in approximately 60% of all cervical cancers worldwide (3) . Carcinogenesis is linked to persistent infection with a high-risk HPV type that may last several years. This suggests that HPVs have evolved mechanisms to evade the immune system.
Three virus-encoded proteins, E5, E6, and E7, have been shown to impact the host's ability to mount an effective immune response. Although little is known about the E5 protein, which is a minor oncoprotein, it has been correlated with decreased cell surface expression of major histocompatibility complex (MHC) molecules and reduced activation of the adaptive immune response (4, 5) . A significant number of studies have demonstrated the myriad of interactions between the E6 and E7 oncoproteins and the host immune system. It has been shown that they cooperate to downregulate expression of a number of inflammatory cytokines, including interleukin-18 (IL-18) and IL-8, and the chemoattractants monocyte chemoattractant protein 1 (MCP-1) and MIP3␣ (6) (7) (8) (9) . Furthermore, they reduce the production of antiviral interferons by subverting the actions of interferon (IFN) regulatory factors (IRFs) (10, 11) and nuclear factor kappa B (NF-B) (12, 13) . More recently, they have been implicated in the reduced production of type III IFNs (14) .
Keratinocytes are the targets for infection by HPVs, and they are capable of responding to a wide array of pathogens by secreting cytokines to attract and activate the innate and adaptive immune responses (15) , in particular interleukin-18 (IL-18), which is a proinflammatory cytokine that plays a protective role against virus infection by regulating the secretion of gamma interferon (IFN-␥) from T H 1 lymphocytes, enhancing the cytotoxicity of natural killer (NK) cells (16) , and bolstering the antiviral capacity of keratinocytes (17, 18) . The proinflammatory effects of IL-18 are counterbalanced by a natural antagonist, IL-18 binding protein (IL-18BP), which acts to suppress the deleterious effects of excessive IL-18 secretion in vivo (19) . Given the critical nature of the IL-18 -IL-18BP axis for regulating inflammatory responses of the skin, it is likely to be a critical factor governing the persistence of skin-tropic viruses. Indeed, poxviruses are known to encode functional IL-18BP homologues, which contribute to virus virulence by downregulating IL-18-mediated inflammatory responses (20) . Despite the body of evidence regarding the importance of IL-18BP for regulating the epithelial inflammatory response, there is cur-rently no published observation of direct virus modulation of endogenous IL-18BP.
This study shows that following stimulation with IFN-␥, primary human keratinocytes expressing E7 produce significantly higher levels of IL-18BP than control cells. Using a panel of established mutants, the CR3 region of E7 was found to be necessary for increased IL-18BP production. The result of the increased IL-18BP production was decreased CD4-positive lymphocyte activation. These results suggest that increased IL-18BP production may be a novel mechanism by which HPV could evade the immune response and persist in the epithelium.
MATERIALS AND METHODS
DNA manipulations. The plasmid pBabe-Puro was used to transiently or stably express E6, E7, or E6/E7 products. Constructs containing E6, E7, or E6/E7 from HPV6, -11, or -16 were provided by Dennis McCance (Queen's University Belfast). The HPV18 E7 sequence was amplified from the full-length HPV18 genome, provided by Sally Roberts (University of Birmingham), and ligated into pBabe-Puro using BamHI and EcoRI sites. HPV16 E7 point and truncation mutants were obtained from Lawrence Banks (ICGEB, Trieste, Italy). The IL-18BP luciferase reporter plasmids have been described previously (21) and were provided by Heiko Muhl (University of Frankfurt, Germany). DNA sequences of all inserts were verified (GATC).
Cell culture. Primary human foreskin keratinocytes were obtained from Sally Roberts and cultured as described previously (22) . Cells were cultured in SFM keratinocyte growth medium (Invitrogen) containing 25 g/ml bovine pituitary extract and 0.1 ng/ml epidermal growth factor (EGF). Cells were passaged for a maximum of 6 passages. NIH J2 3T3 fibroblasts (a gift from Sally Roberts) were cultured in Dulbecco modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS) and 2 mM L-glutamine.
Generation of stable keratinocyte lines containing the HPV18 genome. The HPV18-pGEMII plasmid (Sally Roberts, University of Birmingham), containing the total HPV18 genome (accession number NC_001357), was digested with EcoRI to release the genome, which was then recircularized with T4 ligase (NEB). The genome was cotransfected with a plasmid containing neomycin resistance into SFM keratinocyte growth medium. The cells were selected with 100 g/ml G418 (Roche) E medium containing 5% (vol/vol) serum, 2 mM L-glutamine, and 5 nM EGF for 8 days. Cells were selected on a layer of J2 3T3 fibroblast feeders (NIH) treated with 8 g/ml mitomycin C (Roche).
Retrovirus transduction. Stocks of retrovirus for transduction of primary cells were produced by transfection of the Phoenix packaging cell line. Supernatants from transfected cells were added to target cells with 5 g/ml Polybrene at 37°C. Virus was removed from cells after 6 h of incubation, and cells were fed fresh medium. After 48 h of recovery at 37°C, cells were placed under selection in 5 g/ml puromycin.
Isolation of primary CD4 lymphocytes. Primary cells were extracted and analyzed in accordance with the ethical rules of the University of Hannover Medical School (3362) and the University of Leeds, Faculty of Biological Sciences (BIOSCI09-001). To isolate peripheral blood mononuclear cells (PBMCs), 30 to 60 ml of peripheral blood was collected from healthy donors in sterile Vacutainer lithium heparin (BD Biosciences, Oxford, United Kingdom). Blood was kept at room temperature after donation and used immediately. PBMCs were isolated from peripheral whole blood using density gradients. Peripheral blood was diluted 1:1 with sterile phosphate-buffered saline (PBS) (Gibco, Life Technologies, United Kingdom). An equal amount of diluted blood was then carefully layered onto Ficoll-Paque Plus (GE Healthcare, Buckinghamshire, United Kingdom). This was then centrifuged for 40 min at 400 ϫ g with no brake. PBMCs were then removed and diluted 1:1 with sterile PBS. Cells were then centrifuged at 350 ϫ g for 4 min and supernatant removed. PBMCs were either used immediately or cultured in RPMI 1640 supplemented with 5% fetal calf serum (FCS) (PromoCell, Heidelberg, Germany), 0.5% L-glutamine (Sigma-Aldrich, United Kingdom), and 0.05 mg/ml streptomycin and 50 U/ml penicillin (Sigma-Aldrich, United Kingdom) at 37°C with 5% CO 2 .
PBMCs were centrifuged at 350 ϫ g for 4 min. The supernatant was removed before washing with sterile PBS. Using the CD4 ϩ T cell isolation kit II (Miltenyi Biotec, Surrey, United Kingdom), cells were then stained with magnetic labels as per the manufacturer's instructions. After magnetic labeling, the cells were then put through the LS columns (Miltenyi Biotec, Surrey, United Kingdom) as per the manufacturer's instructions.
CD4-positive lymphocyte activation assay. Stable keratinocyte cell lines were stimulated with IFN-␥ (10 ng/ml) and incubated for 8 h before the cells were washed thoroughly to remove input IFN-␥ and replaced with fresh medium. Cells were incubated for a further 16 h before harvesting. Isolated CD4-positive lymphocytes were stimulated with activating anti-CD3/CD28 (150/200 ng/ml) antibodies and costimulated with IL-18 (20 ng/ml) in the presence of medium taken from keratinocyte cultures. CD4-positive lymphocytes were incubated for 24 h before medium was harvested and analyzed by enzyme-linked immunosorbent assay (ELISA) for secreted IFN-␥ production. Keratinocyte medium was analyzed in parallel to confirm the absence of input IFN-␥.
RNA extraction and qRT-PCR. RNA was extracted from keratinocytes using the Quick-RNA MiniPrep (Zymo Research, Cambridge Bioscience, Cambridge, United Kingdom) and cDNA generated with a cDNA synthesis kit (Fermentas). Reverse transcription-quantitative PCR (qRT-PCR) was performed on a RotorGen (Qiagen, Hilden, Germany) using a ⌬⌬C T -analysis based on the generation of standard curves for both the housekeeping gene (U6snRNA) and the target gene (IL-18BP) (QuantiTect primer assay; Qiagen) using QuantiFast SYBR green PCR (Qiagen).
Lestaurtinib inhibitor assay. HPV18-containing keratinocytes grown on mitomycin C-treated J2 3T3 and primary keratinocytes were treated with 100 nM lestaurtinib (Tocris Biosciences) for 1 h at 37°C prior to stimulation with 10 ng/ml IFN-␥ (BioLegend) for 24 h. Supernatants were collected for ELISA, and cells were lysed for protein analysis.
Determination of IL-18BP and IFN-␥ levels by ELISA. Quantities of cytokines in cell-free supernatants were determined using the R&D Systems ELISA kit according to manufacturer's instructions.
SDS-PAGE and immunoblotting. Cells were lysed in Leeds lysis buffer supplemented with protease inhibitor cocktail (Roche) (23) . Proteins were separated by SDS-PAGE before transfer onto nitrocellulose membrane (HyBond C Extra; Amersham Biosciences). Membranes were probed with primary antibodies against 16E7 (Santa Cruz) and 18E7, GAPDH (glyceraldehyde-3-phosphate dehydrogenase), and pRb (Abcam) and horseradish peroxidase (HRP)-conjugated secondary antibodies (Sigma). Proteins were detected using enhanced chemiluminescence reagent.
Reporter gene assays. Dual-luciferase reporter assays were performed as previously described (24) . Keratinocytes were seeded at 3 ϫ 10 5 cells/ml in 24-well dishes prior to transfection. Cells were transfected with wildtype and mutant IL-18BP promoter-driven firefly luciferase reporters and a Renilla luciferase (RLTK)-expressing plasmid as a transfection control using FuGene reagent. At 24 h posttransfection, cells were stimulated with IFN-␥ (BioLegend) for 12 h prior to lysis in passive lysis buffer (Promega). Firefly luciferase levels were normalized to Renilla levels, and fold induction values were calculated relative to the normalized activity of the mock control.
RESULTS
HPV16 E7 augments IL-18BP expression in primary keratinocytes. To gain insight into a possible effect of HPV oncoproteins on endogenous IL-18BP secretion, primary human foreskin keratinocytes were transduced with retroviruses expressing HPV16 E6 and E7 in isolation or E6/E7 from a bicistronic transcript. Viral gene expression was confirmed by RT-PCR (data not shown). Cells were stimulated with IFN-␥, a potent inducer of IL-18BP (25) , for 16 h and culture supernatants analyzed by ELISA. In control keratinocytes, expressing empty pBabe-Puro plasmid, IFN-␥ induced the secretion of IL-18BP (Fig. 1A) . Expression of 16E6 induced a modest, but statistically significant, increase in the levels of IL-18BP secretion, whereas 16E7 had the most pronounced effect on IL-18BP secretion, inducing more than a doubling in concentrations of cytokine compared with the control. This was not significantly further increased in the presence of E6. These data demonstrate that HPV oncoproteins, in particular E7, enhance the levels of IL-18BP secreted from primary keratinocytes.
E7 proteins from other HPV types enhance IL-18BP expression. This is the first report to demonstrate that HPV16 E7 enhances IL-18BP expression. To establish whether enhanced IL-18BP production was a general feature of E7 proteins, keratinocytes stably expressing E7 proteins from several mucosal types were treated with IFN-␥ and levels of IL-18BP measured by ELISA (Fig. 1B) . E7 from both low-risk (HPV6b and HPV11) and highrisk (HPV16 and HPV18) types increased expression of IL-18BP to comparable levels. These experiments illustrate that IL-18BP is a conserved target for E7 proteins of multiple HPV types, suggesting that increased IL-18BP levels may be necessary during the HPV life cycle rather than associated directly with transformation.
The CR3 region of E7 is necessary for enhanced IL-18BP expression. Next, the regions of E7 important for enhancing IL-18BP production were identified. Primary keratinocytes were transduced with retroviruses expressing a panel of E7 proteins containing mutations in the amino-terminal disordered conserved region 1 (CR1) and CR2 or in the more structured carboxyl-terminal CR3 (25) (26) (27) (28) (29) . Figure 2A shows a schematic diagram of E7 and the mutations examined in this study. E7 proteins containing single-amino-acid mutations in CR1 or CR2 (CR1-H2P or CR2-C24G) retained the ability to increase IL-18BP production upon IFN-␥ treatment (Fig. 2B) . Several mutants containing small production. Primary human foreskin keratinocytes stably expressing empty plasmid (pBabe), 16E7, 16E7 H2P, 16E7 C24G, and four carboxyl-terminal truncations designated ⌬1 (with deletion of amino acids 52 to 56), ⌬2 (with deletion of amino acids 65 to 67), ⌬3 (with deletion of amino acids 75 to 77), and ⌬4 (with deletion of amino acids 79 to 83) were treated with IFN-␥ (10 ng/ml) for 16 h. Following treatment, supernatants were harvested and levels of secreted IL-18BP measured by ELISA. Results are expressed as the means Ϯ SD from four independent experiments. (C) Media and cell lysates from representative experiments were subjected to SDS-PAGE and probed with the indicated antibodies to confirm E7 expression and test functionality of the mutations. GAPDH was used to demonstrate equal loading of lysates. deletions in CR3 of E7 were also tested for their ability to augment IL-18BP production. Keratinocytes stably expressing ⌬1 (with deletion of amino acids 52 to 56) and ⌬4 (with deletion of amino acids 79 to 83) showed IL-18BP levels similar to those in cells expressing wild-type E7 (Fig. 2B) . In contrast, cells expressing ⌬2 (with deletion of amino acids 65 to 67) and ⌬3 (with deletion of amino acids 75 to 77) produced lower levels of IL-18BP, similar to those with vector (pBabe-Puro) alone. While these data imply that amino acids within ⌬2 and ⌬3 are necessary for the increased IL-18BP production, it is plausible that the mutations may have had additional impacts on E7 structure, since CR3 has been shown to be highly structured (30, 31) . To explore whether the panel of mutants used in this study were broadly functional, we tested their expression level and ability to downregulate the cellular Rb protein, a key target for E7 proteins (28) . Stable expression of the mutant proteins was observed (Fig. 2C) , although levels of C24G were reduced compared with those of the wild type. Interestingly, this mutant was still capable of increasing IL-18BP levels, suggesting that only low levels of E7 are necessary for this function. Although E7 has been reported to be secreted into the cell medium and to bind directly to the IL-18 receptor (32), we could not detect E7 in the media of our stable keratinocyte cell lines. As such, it is unlikely that any secreted form of E7 was necessary for the observed effects on IL-18BP (Fig. 2C) .
As previously reported, expression of wild-type E7 reduced Rb levels, while mutations in CR1 (H2P) or CR2 (C24G) abrogated this ability and resulted in Rb levels similar to those for the vector alone (Fig. 2C) . Expression of the CR3 deletions reduced Rb levels equivalently to the wild type, despite any small differences in E7 expression between samples. These data suggest that amino acids within CR3 are required for increased IL-18BP and that the loss of IL-18BP expression seen in the ⌬2 and ⌬3 mutant cell lines is not due to gross changes in E7 structure.
Enhanced IL-18BP expression requires a proximal gammaactivated sequence (GAS) element in the IL-18BP promoter. To address whether the increased levels of IL-18BP protein were due to increased mRNA abundance, time course experiments were performed and levels of mRNA expression determined over a 24-h time period of IFN-␥ treatment using quantitative RT-PCR. IL-18BP transcript was detectable at the 6-h time point in both control and E7-expressing keratinocytes, although transcript levels were significantly greater in those expressing E7 (Fig. 3A) . Tran- script levels continued to increase until the 24-h time point and were greater in all samples containing E7. This trend was also observed with secreted IL-18BP (Fig. 3B) . Despite a delay in protein production until 24 h in the control cells, secreted IL-18BP was detectable at as early as 12 h in cells expressing E7 (Fig. 3B) .
IL-18BP transcription is thought to be dependent on the gamma-activated sequence (GAS) within the IL-18BP promoter element, which can be bound by members of the signal transducer and activator of transcription (STAT) family of transcription factors (33) . The IL-18BP promoter element contains two conserved GASs, one directly adjacent to the transcriptional start site (bp Ϫ25 to Ϫ33) and a second, more distal site, located at bp Ϫ625 to Ϫ633 (21) . To begin to decipher the signaling pathways leading to IL-18BP production in E7-expressing cells, luciferase reporter assays were performed. Control and E7-expressing keratinocytes were transfected with a reporter plasmid driving luciferase expression from the IL-18BP promoter (pGL3-BP WT) (Fig. 3C) . In addition, three further reporter plasmids were used. These constructs contained mutations that inactivated either the proximal (pGL3-BP prox), distal (pGL3-BP dist), or both (pGL3-BP dist/ prox) (21) GASs. Treatment with IFN-␥ induced luciferase expression from the wild-type IL-18BP promoter reporter (Fig. 3C) . Mutation of the proximal, but not the distal, GAS in the promoter significantly reduced luciferase production in response to IFN-␥ treatment in both control and E7-expressing cells. Importantly, the double mutation at the proximal and distal GASs was not associated with any further suppression of luciferase expression compared to that with the single proximal mutant. These results indicate that E7 expression modulates IL-18BP production through the canonical proximal GAS.
It was important to examine the effects of E7 on IL-18BP production in the context of the complete HPV genome in which all viral factors are present. For this, primary human keratinocytes harboring the HPV18 genome were generated using published protocols (22) . Control or HPV18-harboring keratinocytes were incubated with dimethyl sulfoxide (DMSO) (mock) or the smallmolecule Jak kinase inhibitor lestaurtinib (100 nM) (34) for 1 h prior to stimulation with IFN-␥. As seen in Fig. 3D , levels of IL-18BP were significantly reduced in the media of both control and HPV18-containing keratinocytes. Treatment did not significantly alter levels of the E7 protein, suggesting that abrogation of Jak signaling prevents E7-mediated production of IL-18BP. Overall, these data strongly suggest that IL-18BP production requires a functional Jak-STAT signaling pathway in E7-expressing cells.
The enhanced IL-18BP expression by E7 reduces activation of primary CD4-positive lymphocytes. The cellular immune response is essential for destruction of HPV-infected keratinocytes. IL-18 is known to augment this by increasing IFN-␥ secretion from activated T lymphocytes (16) . As IL-18BP antagonizes the effects of IL-18, we wanted to assess the biological consequences of increased IL-18BP production by E7-expressing keratinocytes. Primary human CD4-positive T lymphocytes were isolated from the PBMCs of healthy volunteers and stimulated with anti-CD3/ CD28 antibodies. Activated lymphocytes were subsequently incubated with IL-18 in the presence of medium taken from keratinocytes stably expressing vector alone, wild-type E7, or ⌬2 E7 and analyzed after 24 h for IFN-␥ secretion by ELISA. As shown in Fig.  4 , exposure to media from all keratinocytes caused a reduction in IFN-␥ release from the CD4-positive lymphocytes. This was to be expected since the media contained various levels of IL-18BP. Importantly, exposure to medium from the wild-type-E7-expressing keratinocytes resulted in the most pronounced inhibition of IFN-␥ production. To confirm that increased IL-18BP production was necessary for the reduced IFN-␥ levels produced by the CD4-positive lymphocytes, we assessed the effects of the ⌬2 E7 cell line on IFN-␥ production. CD4-positive lymphocytes incubated in medium from the ⌬2 cell line produced more IFN-␥ than those from the wild-type E7 cell line, with levels resembling those with the vector alone. To preclude the possibility that IFN-␥ was present in the input samples, we tested both the mock samples and keratinocyte medium. These samples contained undetectable levels of IFN-␥. Overall, these data suggest that the increased levels of IL-18BP produced by E7-expressing keratinocytes have an inhibitory effect on CD4-positive lymphocytes.
DISCUSSION
The pathogenesis of HPV infection is directly linked to the immune responses of the host, which depend on the secretion of specific cytokines to attract components of the adaptive immune system to the site of virus infection. However, HPV infections appear to be immunologically deficient and suffer from reduced inflammatory infiltrate (34) . Several mechanisms have been proposed to explain the observed immunodeficiency, and these focus mainly on the E6 and E7 oncoproteins. Both E6 and E7 have been shown to target the IL-18 receptor directly, to prevent activation of target cells (32) . E6 and E7 also prevent the transcription of inflammatory cytokines by targeting antiviral signaling pathways (9, 14, 35) .
Our data provide the first evidence for upregulation of IL-18BP by a virus protein in the context of both overexpression of the individual protein and the stable expression of the entire HPV genome. Given the critical role of IL-18 in the skin inflammatory response to virus infection, which includes increasing the expression of antiviral molecules such as MHC-II (17) , it is likely that the suppressive effects associated with increased IL-18BP present in the vicinity of HPV infection would lead to a diminished cellular immune response associated with HPV infection. The results of this study demonstrate that medium produced from E7-expressing keratinocytes is able to inhibit primary CD4-positive lymphocytes costimulated with IL-18. Importantly, the E7 ⌬2 mutant, which was unable to increase the expression of IL-18BP from keratinocytes, was also not able to inhibit IFN-␥ production from the CD4-positive lymphocytes, suggesting that IL-18BP is necessary for the effects seen in this assay. Despite this, the use of neutralization assays with IL-18BP-specific antibodies would greatly strengthen these findings.
Interestingly, E7 proteins from low-risk HPV6b and -11 were also capable of increasing IL-18BP expression, suggesting that IL-18BP is an important target for E7 and may contribute to HPV persistence in infected individuals. Mapping studies identified residues in the carboxyl CR3 region of E7 necessary for the increased IL-18BP production. This region contributes to a number of E7 functions, including dimerization (36) . It may also mediate interactions with a number of cellular proteins, including cullin 2, HDAC, pCAF, p300, TATA binding protein, and Rb (25, 27, 29, 37, 38) . The interaction of E7 with one or several of these proteins may be important for regulating IL-18BP production.
IL-18BP expression is mediated by a number of response elements found within the IL-18BP promoter, and a proximal GAS element is necessary for IFN-␥-mediated expression (21) . Members of the STAT family of transcription factors bind GAS elements, and HPV proteins have been shown to differentially regulate these proteins during the virus life cycle (39) (40) (41) (42) , which may help to coordinate the pleiotropic effects observed on the immune system. The time course experiments demonstrated earlier kinetics of IL-18BP expression in E7-expressing cells than in controls. This is unlikely due to different signaling pathways and so may indicate that E7 also functions through an as-yet-unidentified pathway or acts on a novel negative regulatory protein that functions to suppress IL-18BP expression.
In conclusion, our results add HPV to the short list of persistent viruses that are currently known to modulate the IL-18-IL-18BP axis. Given the critical nature of IL-18 for mounting the defensive response to virus infection, we propose that IL-18BP is likely to be targeted by a growing number of viruses.
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